Ictal adipokines are associated with pain severity and treatment response in episodic migraine
Citation Manager Formats
Make Comment
See Comments

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Objective: To evaluate ictal adipokine levels in episodic migraineurs and their association with pain severity and treatment response.
Methods: This was a double-blind, placebo-controlled trial evaluating peripheral blood specimens from episodic migraineurs at acute pain onset and 30 to 120 minutes after treatment with sumatriptan/naproxen sodium vs placebo. Total adiponectin (T-ADP), ADP multimers (high molecular weight [HMW], middle molecular weight, and low molecular weight [LMW]), leptin, and resistin levels were evaluated by immunoassays.
Results: Thirty-four participants (17 responders, 17 nonresponders) were included. In all participants, pretreatment pain severity increased with every quartile increase in both the HMW:T-ADP ratio (coefficient of variation [CV] 0.51; 95% confidence interval [CI]: 0.08, 0.93; p = 0.019) and resistin levels (CV 0.58; 95% CI: 0.21, 0.96; p = 0.002), but was not associated with quartile changes in leptin levels. In responders, T-ADP (CV −0.98; 95% CI: −1.88, −0.08; p = 0.031) and resistin (CV −0.95; 95% CI: −1.83, −0.07; p = 0.034) levels decreased 120 minutes after treatment as compared with pretreatment. In addition, in responders, the HMW:T-ADP ratio (CV −0.04; 95% CI: −0.07, −0.01; p = 0.041) decreased and the LMW:T-ADP ratio (CV 0.04; 95% CI: 0.01, 0.07; p = 0.043) increased at 120 minutes after treatment. In nonresponders, the LMW:T-ADP ratio (CV −0.04; 95% CI: −0.07, −0.01; p = 0.018) decreased 120 minutes after treatment. Leptin was not associated with treatment response.
Conclusions: Both pretreatment migraine pain severity and treatment response are associated with changes in adipokine levels. Adipokines represent potential novel migraine biomarkers and drug targets.
GLOSSARY
- ADP=
- adiponectin;
- CI=
- confidence interval;
- CV=
- coefficient of variation;
- HMW=
- high molecular weight;
- ICHD-2=
- International Classification of Headache Disorders, second edition;
- IL-6=
- interleukin 6;
- LEP=
- leptin;
- LMW=
- low molecular weight;
- MMW=
- middle molecular weight;
- NRS=
- numeric rating scale;
- suma/nap=
- sumatriptan/naproxen sodium;
- T-ADP=
- total adiponectin;
- TNF-α=
- tumor necrosis factor α
Footnotes
Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
Supplemental data at Neurology.org
- Received August 11, 2014.
- Accepted in final form December 18, 2014.
- © 2015 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Sevil Yaşar and Dr. Behnam Sabayan
► Watch
Alert Me
Recommended articles
-
Article
Adiponectin and leptin levels in migraineurs in the Atherosclerosis Risk in Communities StudyJennifer L. Dearborn, Andrea L.C. Schneider, Rebecca F. Gottesman et al.Neurology, November 05, 2014 -
Articles
Oligomerization state-dependent elevations of adiponectin in chronic daily headacheB. Lee Peterlin, Guillermo Alexander, David Tabby et al.Neurology, May 12, 2008 -
Brief Communications
Leptin, ghrelin, and adiponectin in epileptic patients treated with valproic acidR. Greco, G. Latini, F. Chiarelli et al.Neurology, December 12, 2005 -
Brief Communications
Serum leptin changes in epileptic patients who gain weight after therapy with valproic acidA. Verrotti, F. Basciani, S. Morresi et al.Neurology, July 01, 1999


